All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Correlation between IGF-I and chemotherapy-related toxicities in childhood ALL
|
An evaluation of the role of IGF-I in children with ALL undergoing chemotherapy has been published in the International Journal of Molecular Sciences by Kocadag et al.1 This study investigated the fluctuations in IGF-I levels during treatment and how this correlated with tissue damage and inflammation. These data were used to determine the potential for IGF-I to be used as a biomarker for chemotherapy-related toxicities.1 |
| Key learnings |
|
IGF-I levels were found to be significantly reduced at diagnosis but then increased after chemotherapy initiation, peaking on Day 8. This rise indicates an IGF-I response to chemotherapy-induced tissue damage. |
|
Increases in IGF-I were positively correlated with inflammatory markers, including CRP and IL-6, suggesting that IGF-I may indicate systemic inflammation. |
|
Among patients with a larger increase in IGF-I from Day 1 to Day 15, there was a correlation with a slower recovery from chemotherapy-induced intestinal damage. |
|
Patients with higher IGF-I levels on Day 8 had an increased likelihood of severe intestinal mucositis on Day 15 (p = 0.02). |
|
These data suggest IGF-I may be feasible as an early biomarker for chemotherapy-induced tissue injury and systemic inflammation, with potential to guide treatment strategies in childhood ALL. |
Abbreviations: ALL, acute lymphoblastic leukemia; CRP, C-reactive protein; IGF-I, insulin-like growth factor-I; IL, interleukin.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content